@article{116a152d280b4ab79f4fdf50b63f7d27,
title = "Infants Receiving a Single Dose of Nirsevimab to Prevent RSV Do Not Have Evidence of Enhanced Disease in Their Second RSV Season",
abstract = "To characterize nirsevimab in the prevention of RSV, children from the Phase 3 MELODY trial were followed through their second RSV season. No increase in medically attended RSV lower respiratory tract infections or evidence of antibody-dependent enhancement of infection or disease severity was found for nirsevimab vs placebo recipients.",
keywords = "immunization, monoclonal antibody, nirsevimab, respiratory syncytial virus",
author = "{MELODY Study Group} and Ron Dagan and Hammitt, {Laura L.} and Nu{\~n}ez, {Beatriz Seoane} and Cots, {Manuel Baca} and Miroslava Bosheva and Madhi, {Shabir A.} and Muller, {William J.} and Zar, {Heather J.} and Yue Chang and Alexander Currie and Amy Grenham and Manish Shroff and Therese Takas and Mankad, {Vaishali S.} and Amanda Leach and Tonya Villafana",
note = "Publisher Copyright: {\textcopyright} The Author(s) 2024. Published by Oxford University Press on behalf of The Journal of the Pediatric Infectious Diseases Society.",
year = "2024",
month = feb,
day = "1",
doi = "10.1093/jpids/piad113",
language = "English (US)",
volume = "13",
pages = "144--147",
journal = "Journal of the Pediatric Infectious Diseases Society",
issn = "2048-7193",
publisher = "Oxford University Press",
number = "2",
}